Regencell Bioscience (US:RGC) — Company Overview, News & Financial Data
Regencell Bioscience develops traditional Chinese medicine biopharmaceuticals for chronic diseases and neurological disorders.
Regencell Bioscience
Regencell Bioscience (NASDAQ:RGC) focuses on developing traditional Chinese medicine bio-pharmaceutical remedies aimed at treating a range of chronic diseases and conditions. This innovative company is keen on leveraging natural plant and herb extracts, combined with scientific methods, to formulate treatments that address neurological disorders, metabolic diseases, and other health challenges. Their projects span extensive research and development efforts to blend the wisdom of traditional remedies with modern biotechnological advancements. Regencell's primary objective is to provide effective, natural-based therapeutic options to people worldwide, aiming to improve patient outcomes and quality of life through their groundbreaking work in the bioscience domain.
Snapshot
Operations
Products and/or services of Regencell Bioscience
- Traditional Chinese Medicine (TCM) based therapeutics for chronic diseases, focusing on metabolic, neurodegenerative, and age-related conditions.
- Development of botanical drug candidates targeting diabetes and its complications.
- Research on natural compounds for the possible treatment of Alzheimer's disease.
- Exploration of TCM formulations aiming to mitigate symptoms and progression of Parkinson's disease.
- Investigations into herbal-based interventions for improving cognitive function and memory.
- Products designed for enhancing general wellness, including supplements for immune system support.
Regencell Bioscience executive team
- Mr. Yat-Gai AuFounder, Chairman & CEO
- Ms. Michelle ChanFinancial Controller, CFO & Principal Financial Officer
- Mr. Wai Hong ChungCOO, Chief Strategy Officer & Director
- Ms. Antonia AssangSenior Vice President of Project Management
- Mr. Yat-Pui AuChief Business Officer